InvestorsHub Logo
Followers 32
Posts 2803
Boards Moderated 3
Alias Born 10/24/2015

Re: None

Thursday, 08/04/2022 3:55:03 PM

Thursday, August 04, 2022 3:55:03 PM

Post# of 386
(OT): From this, ''One approach that’s gaining traction involves induced pluripotent stem cells, or IPSCs. These cells can reproduce indefinitely and be developed into any other cell type. Though researchers have struggled to transform them into the adult T cells capable of fighting cancers, recent progress has led biotech companies like Century Therapeutics and Fate Therapeutics to try.

The new startup from ElevateBio and Boston Children’s will be next in line. Daley says that, after about a decade of research, his lab “learned how to coax [IPSCs] into making more mature T cells that are comparable to the T cells that we would harvest from a patient's circulating blood.”

The research published Thursday describes a method by which scientists suppress an enzyme, dubbed EZH1, that hampers IPSCs’ ability to become mature T cells. Boston Children’s scientists also tried a different approach to growing the cells, leading to T cells with tumor-fighting power comparable to ones derived from currently used methods, the paper said. The cells were better able to clear cancer in mice than cells made with other IPSC approaches, researchers claimed.'' https://www.biopharmadive.com/news/elevatebio-boston-childrens-startup-cell-therapy-ipsc-daley/628874/
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent FATE News